| Entry |
|
|---|
| Name |
Letrozole (JAN/USP/INN);
Femara (TN) |
|---|
| Product |
|
|---|
| Generic |
LETROZOLE (A-S Medication Solutions), LETROZOLE (Accord Healthcare), LETROZOLE (Aurobindo Pharma Limited), LETROZOLE (AvKARE), LETROZOLE (AvPAK), LETROZOLE (Avet Pharmaceuticals), LETROZOLE (Breckenridge Pharmaceutical), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Chartwell RX), LETROZOLE (Dr. Reddy's Laboratories Limited), LETROZOLE (Natco Pharma Limited), LETROZOLE (NuCare Pharmaceuticals), LETROZOLE (NuCare Pharmaceuticals), LETROZOLE (Proficient Rx LP), LETROZOLE (Teva Pharmaceuticals USA), LETROZOLE (Upsher-Smith Laboratories), LETROZOLE (Yiling Pharmaceutical) |
|---|
| Formula |
C17H11N5
|
|---|
| Exact mass |
285.1014
|
|---|
| Mol weight |
285.30
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01596 Aromatase inhibitor
DG01524 Triazole antineoplastic
Metabolizing enzyme substrate
DG01638 CYP2A6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01525 CYP2A6 inhibitor
|
|---|
| Remark |
| Product (mixture): | D11068<US> |
|
|---|
| Efficacy |
Antineoplastic, Estrogen biosynthesis inhibitor |
|---|
| Disease |
Breast cancer, postmenopausal (HR positive) [DS: H00031] |
|---|
| Comment |
Aromatase inhibitor
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2A6 [HSA: 1548]
|
|---|
| Interaction |
CYP inhibition: CYP2A6 [HSA: 1548]
|
|---|
| Structure map |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BG Aromatase inhibitors
L02BG04 Letrozole
D00964 Letrozole (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Aromatase Inhibitors
Letrozole
D00964 Letrozole (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
252 Genital organ agents
2529 Others
D00964 Letrozole (JAN/USP/INN)
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D00964 Letrozole (JAN/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01596 Aromatase inhibitor
D00964 Letrozole
DG01524 Triazole antineoplastic
D00964 Letrozole
Metabolizing enzyme substrate
DG01638 CYP2A6 substrate
D00964 Letrozole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00964 Letrozole
Metabolizing enzyme inhibitor
DG01525 CYP2A6 inhibitor
D00964 Letrozole
Drug classes [BR:br08332]
Antineoplastic
DG01596 Aromatase inhibitor
D00964 Letrozole
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Cytochrome P450
CYP19A1 (ARO)
D00964 Letrozole (JAN/USP/INN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00964
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00964
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D00964
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 22
1 C1c C 25.6900 -19.1281
2 C8y C 26.8966 -19.8333
3 C8y C 24.4834 -19.8276
4 N4y N 25.6957 -17.7232
5 C8x C 26.8907 -21.2381
6 C8x C 28.1149 -19.1338
7 C8x C 24.4834 -21.2266
8 C8x C 23.2710 -19.1222
9 C8x C 24.5650 -16.9072
10 N5x N 26.8326 -16.9072
11 C8x C 28.1033 -21.9376
12 C8x C 29.3273 -19.8450
13 C8x C 23.2710 -21.9259
14 C8x C 22.0527 -19.8276
15 N5x N 25.0022 -15.5723
16 C8x C 26.4069 -15.5723
17 C8y C 29.3216 -21.2498
18 C8y C 22.0527 -21.2266
19 C3b C 30.5165 -21.9435
20 C3b C 20.8402 -21.9202
21 N3a N 31.7172 -22.6371
22 N3a N 19.6394 -22.6430
BOND 24
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 2
5 2 6 1
6 3 7 2
7 3 8 1
8 4 9 1
9 4 10 1
10 5 11 1
11 6 12 2
12 7 13 1
13 8 14 2
14 9 15 2
15 10 16 2
16 11 17 2
17 13 18 2
18 17 19 1
19 18 20 1
20 19 21 3
21 20 22 3
22 12 17 1
23 14 18 1
24 15 16 1
|
|---|
